Creso Pharma Limited
COPHF · OTC
12/31/2023 | 6/30/2023 | 12/31/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $12 | $7 | $4 | $4 |
| % Growth | 69.8% | 60.8% | 0.7% | – |
| Cost of Goods Sold | $3 | $13 | $11 | -$2 |
| Gross Profit | $9 | -$6 | -$6 | $6 |
| % Margin | 71.5% | -88.2% | -141.6% | 149.3% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $5 | $0 | $0 | $6 |
| SG&A Expenses | -$0 | $6 | $6 | $2 |
| Sales & Mktg Exp. | $1 | $0 | $0 | $2 |
| Other Operating Expenses | -$4 | -$0 | $0 | $12 |
| Operating Expenses | -$4 | $6 | $6 | $14 |
| Operating Income | -$4 | -$12 | -$12 | -$7 |
| % Margin | -36.3% | -176.3% | -277% | -173.1% |
| Other Income/Exp. Net | -$3 | -$16 | -$14 | $0 |
| Pre-Tax Income | -$7 | -$28 | -$26 | -$7 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$24 | -$28 | -$26 | -$7 |
| % Margin | -202.6% | -403.9% | -587.7% | -165.4% |
| EPS | 7.8 | -7.8 | -10.04 | 10.018 |
| % Growth | 200% | 22.3% | -200.2% | – |
| EPS Diluted | 7.8 | -7.8 | -10.04 | 10.018 |
| Weighted Avg Shares Out | 0 | 4 | 3 | 1,463 |
| Weighted Avg Shares Out Dil | 0 | 4 | 3 | 1,463 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $5 | $5 | $0 | $0 |
| Depreciation & Amortization | -$1 | $1 | $2 | $0 |
| EBITDA | -$3 | -$22 | -$23 | $6 |
| % Margin | -25.8% | -315% | -536.3% | 133.2% |